FDA’s Strategic Approach for Combating Antimicrobial Resistance

Scott Gottlieb's discusses FDA's Antimicrobial Resistance Strategies.

Ex-FDA Commissioner Scott Gottlieb’s talk on FDA Antimicrobial Resistance Strategies:

“The FDA is also committed to facilitating innovation through proactive engagement with sponsors and researchers to identify and address challenges to the development and approval of novel and non-traditional antibiotic products. The FDA’s biologics center is actively promoting development of non-traditional products in three major categories. These include bacteriophage, live biotherapeutic products and fecal microbiota for transplantation.”

Read full speech